OPKO HEALTH, INC. (OPK): debt financing — OPKO extends $55M convertible notes maturity to Jan 2025, lowers conversion price to $1.66

OPKO HEALTH, INC.

Original $55M 5% convertible notes due Feb 2023 amended to extend maturity to Jan 31, 2025.
Conversion price reset to $1.66 (10-day VWAP plus 25% premium), down from $5.00 per share.
Interest continues to accrue from last payment date; other terms unchanged.
Notes and shares issuable upon conversion were not registered under Securities Act, relying on Section 4(a)(2) exemption.

item 1.01 item 2.03 item 3.02

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

OPKO HEALTH, INC. amended convertible notes at 5% maturing extend the maturity to January 31, 2025.

Instrument: convertible notes
Rate: 5%
Maturity: extend the maturity to January 31, 2025
Event: amendment

Exact text from the filing

On or about February 10, 2023, the Company amended the Notes to extend the maturity to January 31, 2025, and to reset the conversion price to the 10 day volume weighted average price immediately preceding the date of the amended note, plus a 25% conversion premium, or $1.66.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OPKO HEALTH, INC. amended 5% Convertible Promissory Notes with each holder of a Note (effective 2023-02-10).

Action: amendment
Agreement: notes offering
Counterparty: each holder of a Note
Effective: 2023-02-10

Exact text from the filing

On or about February 10, 2023, the Company amended the Notes to extend the maturity to January 31, 2025, and to reset the conversion price to the 10 day volume weighted average price immediately preceding the date of the amended note, plus a 25% conversion premium, or $1.66.

View on SEC.gov

Browse all debt financings →

OPKO HEALTH, INC. filing history →

Source: SEC EDGAR

accession 0000944809-23-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.